Laryngeal neuroendocrine neoplasm
diseaseOn this page
Also known as laryngeal neuroendocrine tumourlarynx NETlarynx neuroendocrine neoplasmlarynx neuroendocrine tumorlarynx neuroendocrine tumor, well differentiated, low or intermediate gradelarynx neuroendocrine tumourneuroendocrine neoplasm of larynxneuroendocrine neoplasm of the larynx
Summary
Laryngeal neuroendocrine neoplasm (MONDO:0015070) is a cancer. A subtype of head and neck neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Phenotypes (HPO): 14
Clinical features
Signs & symptoms
Clinical features (HPO)
14 HPO clinical features (Orphanet curated; top 14 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0100605 | Neoplasm of the larynx | Obligate (100%) |
| HP:0100634 | Neuroendocrine neoplasm | Obligate (100%) |
| HP:0001618 | Dysphonia | Frequent (30-79%) |
| HP:0001824 | Weight loss | Frequent (30-79%) |
| HP:0002039 | Anorexia | Frequent (30-79%) |
| HP:0002730 | Chronic noninfectious lymphadenopathy | Frequent (30-79%) |
| HP:0002875 | Exertional dyspnea | Frequent (30-79%) |
| HP:0003144 | Increased serum serotonin | Frequent (30-79%) |
| HP:0003528 | Elevated calcitonin | Frequent (30-79%) |
| HP:0012432 | Chronic fatigue | Frequent (30-79%) |
| HP:0200136 | Oral-pharyngeal dysphagia | Frequent (30-79%) |
| HP:0011749 | Adrenocorticotropic hormone excess | Very rare (<1-4%) |
| HP:0031029 | Elevated carcinoembryonic antigen level | Very rare (<1-4%) |
| HP:0031218 | Inappropriate antidiuretic hormone secretion | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | laryngeal neuroendocrine neoplasm |
| Mondo ID | MONDO:0015070 |
| Orphanet | 100083 |
| DOID | DOID:5457 |
| ICD-11 | 1502591214 |
| NCIT | C6023 |
| SNOMED CT | 707625001 |
| UMLS | C1334374 |
| MedGen | 232692 |
| GARD | 0019758 |
| Anatomy (UBERON) | UBERON:0001737 |
| Is cancer (heuristic) | yes |
Also known as: laryngeal neuroendocrine neoplasm · laryngeal neuroendocrine tumour · larynx NET · larynx neuroendocrine neoplasm · larynx neuroendocrine tumor · larynx neuroendocrine tumor, well differentiated, low or intermediate grade · larynx neuroendocrine tumour · neuroendocrine neoplasm of larynx · neuroendocrine neoplasm of the larynx
Disease family
This is a subtype of head and neck neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › head and neck neoplasm › laryngeal neuroendocrine neoplasm
Related subtypes (36): cranial nerve neoplasm, cavernous hemangioma of face, gasserian ganglion meningioma, nasal cavity neoplasm, palatal neoplasm, nasopharyngeal neoplasm, head and neck cancer, head and neck paraganglioma, nasal cavity and paranasal sinus lethal midline granuloma, familial thyroglossal duct cyst, laryngotracheal angioma, facial dermoid cyst, epignathus, nasal glial heterotopia, nasal ganglioglioma, malignant epithelial tumor of salivary glands, benign epithelial tumor of salivary glands, juvenile nasopharyngeal angiofibroma, recurrent respiratory papillomatosis, ocular adnexal lymphoma, gingival neoplasm, odontogenic neoplasm, eye neoplasm, ear neoplasm, tongue neoplasm, buccal mucosa neoplasm, lip neoplasm, tonsil neoplasm, neoplasm of neck, tumor of salivary gland, neoplasm of hypopharynx, neoplasm of oropharynx, neoplasm of floor of mouth, lipoma of face, skull neoplasm, nasal cavity and paranasal sinus neoplasm
Subtypes (1): laryngeal small cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.